Edna Cheung

Edna Cheung

Auto-generated profile, based on publicly available information

Edna Cheung

Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2013 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
ASAdam Schickedanz
Adam Schickedanz
DHDavid Huang
David Huang
ALAndrea Lopez
Andrea Lopez
ECEdna Cheung
Edna Cheung
CLC. R. Lyles
C. R. Lyles
USUrmimala Sarkar
Urmimala Sarkar

21 January 2019 in Annals of Hematology
Verified
Journal Article
Closed access
ECEdna Cheung
Edna Cheung
APAnthony J. Perissinotti
Anthony J. Perissinotti
DBDale L. Bixby
Dale L. Bixby
PBPatrick W. Burke
Patrick W. Burke
KPKristen M. Pettit
Kristen M. Pettit
BMBernard L. Marini
Bernard L. Marini

1 January 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CUClaudia Uhde-Stone
Claudia Uhde-Stone
ECEdna Cheung
Edna Cheung
BLBiao Lu
Biao Lu

1 April 2016 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
TKTaiyi Kuo
Taiyi Kuo
PLPatty H. Liu
Patty H. Liu
TCTzu-Chieh Chen
Tzu-Chieh Chen
RLRebecca A. Lee
Rebecca A. Lee
JNJenny New
Jenny New
JWJen-Chywan Wang
Jen-Chywan Wang
Glucocorticoids and FoxO3 exert similar metabolic effects in skeletal muscle. FoxO3 gene expression was increased by dexamethasone (Dex), a synthetic glucocorticoid, both in vitro and in vivo. In C2C12 myotubes the increased expression is due to, at least in part, the elevated rate of FoxO3 gene transcription. In the mouse FoxO3 gene, we identified three glucocorticoid receptor (GR) binding regions (GBRs): one being upstream of the transcription start site, −17kbGBR; and two in introns, +45kbGBR and +71kbGBR. Together, these three GBRs contain four 15-bp glucocorticoid response elements (GREs). Micrococcal nuclease (MNase) assay revealed that Dex treatment increased the sensitivity to MNase in the GRE of +45kbGBR and +71kbGBR upon 30- and 60-min Dex treatment, respectively. Conversely, Dex treatment did not affect the chromatin structure near the −17kbGBR, in which the GRE is located in the linker region. Dex treatment also increased histone H3 and/or H4 acetylation in genomic regions near all three GBRs. Moreover, using chromatin conformation capture (3C) assay, we showed that Dex treatment increased the interaction between the −17kbGBR and two genomic regions: one located around +500 bp and the other around +73 kb. Finally, the transcriptional coregulator p300 was recruited to all three GBRs upon Dex treatment. The reduction of p300 expression decreased FoxO3 gene expression and Dex-stimulated interaction between distinct genomic regions of FoxO3 gene identified by 3C. Overall, our results demonstrate that glucocorticoids activated FoxO3 gene transcription through multiple GREs by chromatin structural change and DNA looping.

20 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EPErrol James Philip
Errol James Philip
FWFrancis Wright
Francis Wright
DKDaniel Myung Kim
Daniel Myung Kim
DKDaniel Kwon
Daniel Kwon
HHHansen Ho
Hansen Ho
VKVadim S Koshkin
Vadim S Koshkin
502 Background: ICIs are effective agents in metastatic urothelial carcinoma in both platinum-refractory and frontline settings. Responses in patients (pts) with non-urothelial histological variants are not well defined. Methods: We undertook a retrospective analysis of pts with metastatic bladder cancer treated with ICI monotherapy. Pts were identified as having a variant histology if any non-urothelial component was present. Fisher’s exact test was used to assess differences in ORR by histology. Results: Between 12/2014 and 10/2019, 102 pts received ICI monotherapy, of whom 93 were evaluable for response and 33 had variant histology. Median age was 70 yrs, 66% were male, 50% received prior platinum-based chemotherapy. Most received pembrolizumab (66%) or atezolizumab (33%). ORR in the overall cohort was 26% (15% PR, 11% CR), with 12% having SD. Histology breakdown and responses are shown in Table. Although twice as many responses were seen in urothelial pts as in pts with variant histologies (ORR 31% vs 15%), this difference was non-significant (p = 0.14). Conclusions: In this large single-institution cohort, ORR in a heterogeneous population of bladder cancer pts was consistent with data previously reported in clinical trials. Pts with variant histologies had numerically lower responses relative to pure urothelial histology, but this difference was not statistically significant. Clinical benefit to ICIs was seen across multiple variant histologies suggesting potential efficacy in this patient population that should be confirmed prospectively.[Table: see text]

2 March 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
ECEdna Cheung
Edna Cheung
HBHala T Borno
Hala T Borno
While bone-modifying agents such as bisphosphonates and denosumab are crucial to preventing skeletal-related events in patients with bone metastases, the optimal duration remains undefined. Extended duration may be associated with adverse effects such as osteonecrosis of the jaw and atypical femoral fracture. Although uncommon, atypical femoral fracture represents a serious consequence of prolonged bone-modifying agent use and are characterized by a prodrome and distinct radiographic findings. The oncology setting encompasses a unique set of atypical femoral fracture risk factors and considerations, with hormonal therapy in early stage disease, bone metastases in the advanced setting, and new targeted agents that may affect bone homeostasis. As outcomes in cancer treatment continue to improve, the questions of risks versus benefits of long-term bone-modifying agents and how to mitigate atypical femoral fracture risk become increasingly pertinent.